Another study set out to explore this connection, studying breast cancer cells with overexpression of the HER-2 protein treated with trastuzumab, particularly regarding its ADCC mechanism, that is, the antibody-dependent cellular cytotoxicity. Here, ERBB2 is linked to breast carcinoma.